This inventor holds 178 USPTO granted patents and 28 published patent applications, plus 36 CIPO patents and 67 EPO patents, primarily in Antiviral Compounds (CPC class A61K45-06). Top assignees: Janssen Sciences Ireland Uc, Janssen Sciences Ireland Unlimited Company, Katholieke Universiteit Leuven. Active years: 2009-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Location History:
- Mechelen, BE (2013 - 2016)
- Sterrebeek, BE (2009 - 2018)
- Wavre, IE (2019)
- Rosieres, BR (2020)
- Rosieres, FR (2020 - 2021)
- Beerse, BE (2013 - 2023)
- Wavre, FR (2023)
- Rosieres, BE (2013 - 2024)
- Wavre, BE (2019 - 2024)
Company Filing History:
71 out of 111 
25 out of 64 
20 out of 632 
Years Active: 2009-2024
Areas of Expertise:
Title: Pierre Jean-Marie Bernard Raboisson: Pioneering Innovations in Pharmaceutical Research
Introduction:
Pierre Jean-Marie Bernard Raboisson is a highly accomplished inventor and researcher hailing from Rosieres, Belgium. With an impressive portfolio of 164 patents, he has made significant contributions to the field of pharmaceutical sciences, specifically in the area of PD-L1 targeting. This article delves into his latest patents, career highlights, notable collaborations, and recognizes his invaluable contributions to the world of inventions and patents.
Latest Patents:
Pierre Jean-Marie Bernard Raboisson's latest patents revolve around the development of compounds that serve as inhibitors of PD-1, PD-L1, or the PD-1/PD-L1 interaction. These compounds have been found to have potential therapeutic applications in treating various PD-L1 related diseases, including liver diseases, cancer (hepatocellular carcinoma), viral diseases, and hepatitis B. The pharmaceutical compositions involving these compounds offer promising avenues for advanced treatment options.
Career Highlights:
Throughout his illustrious career, Raboisson has made a significant impact in the pharmaceutical industry. His inventive mindset and dedication have led to the discovery of key compounds and methodologies that have the potential to revolutionize disease treatment. Raboisson's patents exemplify his innovative approach and his relentless pursuit of improving healthcare outcomes.
Collaborations:
Raboisson has collaborated with esteemed organizations in the pharmaceutical domain, notably with Janssen Sciences Ireland Uc and Janssen Sciences Ireland Unlimited Company. These collaborations have allowed him to work alongside influential experts in the industry, such as Tim Hugo Maria Jonckers and David Craig McGowan. Together, they have shared their knowledge and expertise, bringing groundbreaking inventions to fruition.
Conclusion:
Pierre Jean-Marie Bernard Raboisson's career as an inventor and researcher in the field of pharmaceutical science has been characterized by his relentless pursuit of innovative solutions. With his extensive patent portfolio and his recent breakthroughs in targeting PD-L1, Raboisson has demonstrated his ability to contribute significantly to the advancement of medical treatments. His collaborations with prominent pharmaceutical companies and esteemed colleagues further reflect his dedication to pushing the boundaries of medical science. As the world continues to face complex healthcare challenges, Raboisson's work serves as an inspiration for future researchers and inventors seeking to make a lasting impact in the field of healthcare innovations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile